Clinical trials: Demyelinating Disorder
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.
- Trial name
- NCT05014724
- Testing
- Rozanolixizumab
- Sponsor
- UCB Biopharma SRL
Multiple Sclerosis
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
To evaluate the effectiveness, safety and Patient-Reported Outcomes (PROs) of cladribine tablets in participants with RMS including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis…
- Trial name
- NCT03933202
- Testing
- Cladribine Tablets
- Where
- 66 sites in United States
- Volunteers
- 291 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
Single-Dose Study of a New Formulation of BIIB061
The primary objective of the study is to assess the pharmacokinetic (PK) profile of BIIB061 in the new oral formulation in the fasted state in healthy male and female volunteers.
- Trial name
- NCT02521545
- Testing
- BIIB061
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Biogen
Central Nervous System (CNS) Demyelinating Disease, Multiple Sclerosis
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants
The primary objective of this study is to assess the safety and tolerability of a single dose and multiple doses of BIIB033 administered to healthy adult Japanese participants.
- Trial name
- NCT02641041
- Testing
- BIIB033
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Biogen
Positron-Emission Tomography, Multiple Sclerosis
Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers
PET (positron emission tomography) imaging with BAY85-8101 for investigation in patients with Multiple Sclerosis compared to healthy volunteers
- Trial name
- NCT01031199
- Testing
- F-18 FEDAA1106 (BAY85-8101)
- Where
- 2 sites in Australia, Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Multiple Sclerosis, MS
Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response
To develop a test to characterize and monitor Multiple Sclerosis (MS) disease status and therapy response from a participant's home by analyzing the gene expression from participant self-collected blood samples using a novel…
- Trial name
- EMPOWER (NCT03316404)
- Where
- United States
- Volunteers
- 1,168 people
- Sponsor
- DxTerity Diagnostics
Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS…
- Trial name
- GAVOTTE (NCT04548999)
- Testing
- Ocrelizumab, Antihistamine, Methylprednisolone
- Where
- 147 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Hoffmann-La Roche
X-Linked Adrenoleukodystrophy
A Study to Prospectively Assess Disease Progression in Male Children With X-ALD
This is a non-interventional, multi-center study that follows general principles of periodic assessment of X-ALD patients in routine practice.
- Trial name
- NCT03278899
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- NeuroVia, Inc.
Relapsing-remitting Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)
- Trial name
- FREEDOMS (NCT00289978)
- Testing
- Fingolimod 1.25 mg, Fingolimod 0.5 mg
- Where
- 115 sites in Australia, Belgium and 17 more
- Volunteers
- 1,272 people
- Sponsor
- Novartis
Multiple Sclerosis
Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance
Phase IV, multi-center, non-treatment, observational, registry study to determine long term effects of AVONEX® therapy on EDSS, MRI, QoL, and cognition.
- Trial name
- CHAMPIONS CONT (NCT01156298)
- Where
- United States
- Volunteers
- 383 people
- Sponsor
- Biogen
Neuromyelitis Optica Spectrum Disorder
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to < 18 years of age with recently active neuromyelitis optica…
- Trial name
- NCT05549258
- Testing
- Inebilizumab
- Where
- 19 sites in United States, Argentina and 9 more
- Volunteers
- 15 people
- Sponsor
- Amgen
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
The primary objective of this study is to evaluate the efficacy of natalizumab 300 milligrams (mg) subcutaneous (SC) every 4 weeks (Q4W) administrations up to 24 weeks in Japanese participants with relapsing-remitting multiple…
- Trial name
- NCT05265728
- Testing
- Natalizumab
- Where
- 12 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
General Note: throughout this record, "Rebif® New Formulation" is used for historical and consistency purposes. Objectives: Primary: To evaluate the efficacy of Rebif® New Formulation (Interferon-beta-1a [IFN-beta-1a], RNF)…
- Trial name
- IMPROVE (NCT00441103)
- Testing
- Rebif® New Formulation (IFN-beta-1a, RNF)
- Volunteers
- 180 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Invasive Group B Streptococcus Disease, Group B Streptococcus
Comprehensive Outcomes Monitoring for Peri- and Postnatal Invasive Group B Strep Sequelae (COMPPASS) Registry
The goal of this registry is to collect and store important medical and non-health information on children from 0 to 18 years of age affected by early- (up to 24 hours after birth) and late-onset (up to 90 days after birth)…
- Conditions
- Invasive Group B Streptococcus Disease, Group B Streptococcus, Group B Streptococcal Infection, Group B Streptococcus (GBS) Disease
- Trial name
- COMPPASS (NCT06896526)
- Volunteers
- 10,000 people
- Sponsor
- Precia Group
Refractory Lupus Nephritis, Myasthaenia Gravis
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been…
- Conditions
- Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA)
- Trial name
- KYSA-4 (NCT07403188)
- Testing
- KYV-101
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Kyverna Therapeutics
Multiple Sclerosis
JC-Virus (JCV) Antibody Program
The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for such treatment.
- Trial name
- STRATIFY-1 (NCT01070823)
- Testing
- Tysabri® (natalizumab)
- Where
- 11 sites in United States
- Volunteers
- 1,096 people
- Sponsor
- Biogen
NMO Spectrum Disorder
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
The objectives of this phase Ib study are to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenic profiles of B001 in subjects with aquaporin-4 antibody (AQP4-IgG) positive NMOSD.
- Trial name
- NCT05145361
- Testing
- B001 injection
- Where
- 4 sites in China
- Volunteers
- 45 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Multiple Sclerosis
Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS
The purpose of this study is to find out if cannabis-based medicine compared to a dummy medicine (placebo that contains no active ingredient) can help the central neuropathic pain patients experience as a result of multiple…
- Trial name
- NCT00391079
- Testing
- Sativex
- Where
- 6 sites in Canada
- Volunteers
- 339 people
- Sponsor
- GW Pharmaceuticals Ltd
Relapsing-Remitting Multiple Sclerosis
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
This study will be a single center, retrospective, pilot study to determine the effect of Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total lymphocyte counts, grade of lymphopenia, Cluster of…
- Trial name
- NCT03284970
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis
The purpose of this study is to evaluate safety and clinical efficacy of DC-TAB in multiple sclerosis.
- Trial name
- NCT02442570
- Testing
- recombinant human alpha B-crystallin
- Where
- 5 sites in Bulgaria
- Volunteers
- 32 people
- Sponsor
- Delta Crystallon BV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.